RT Journal Article
SR Electronic
T1 Severe Sarcoidosis Demonstrates Heterogenous Immune Dysregulation Across Different Peripheral Immune Cell Types: A Single-Center Single Cell Multi-omic Analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.18.24313886
DO 10.1101/2024.09.18.24313886
A1 Huang, Kai
A1 Vagts, Christen
A1 Ascoli, Christian
A1 Huang, Yue
A1 Sweiss, Nadera J.
A1 Finn, Patricia W.
A1 Perkins, David L.
YR 2024
UL http://medrxiv.org/content/early/2024/09/19/2024.09.18.24313886.abstract
AB Sarcoidosis provides unique management challenges due to variable presentation and disease course. In this single-center analysis, we assess transcriptomic and epigenomic differentiators between severe and mild cases of sarcoidosis using peripheral blood. We showcase differences across multiple cell types that highlight decreased immunoregulation and increased inflammation in severe sarcoidosis. We provide an overall framework for the interactions between immune cells in severe sarcoidosis as a basis for future therapeutic research.Competing Interest StatementThe authors have declared no competing interest.Funding StatementF30HL151182, T32HL144909, R01HL138628. This research has been funded by the University of Illinois at Chicago Center for Clinical and Translational Science (CCTS) award UL1TR002003.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB Ethics Review Committee of University of Illinois Chicago (UIC) gave ethical approval for this work under the following protocols: #2016-0063 and #2018-1038. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced will be made publicly available via GEO once the manuscript is accepted for publication.